tebipenem pivoxil hydrobromide - Profile
What are the generic sources for tebipenem pivoxil hydrobromide and what is the scope of patent protection?
Tebipenem pivoxil hydrobromide
is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for tebipenem pivoxil hydrobromide
Generic Entry Date for tebipenem pivoxil hydrobromide*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for tebipenem pivoxil hydrobromide
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | UTEBZI | tebipenem pivoxil hydrobromide | TABLET;ORAL | 215960-001 | Jun 17, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Glaxosmithkline | UTEBZI | tebipenem pivoxil hydrobromide | TABLET;ORAL | 215960-001 | Jun 17, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Glaxosmithkline | UTEBZI | tebipenem pivoxil hydrobromide | TABLET;ORAL | 215960-001 | Jun 17, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Glaxosmithkline | UTEBZI | tebipenem pivoxil hydrobromide | TABLET;ORAL | 215960-001 | Jun 17, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for tebipenem pivoxil hydrobromide
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2018215687 | ⤷ Start Trial | |
| Australia | 2020281120 | ⤷ Start Trial | |
| Brazil | 112019015487 | ⤷ Start Trial | |
| Canada | 3049690 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
